FreeTheAI

ImmunityBio Shares Fall Despite 3-Year Data Showing 84% Cystectomy Avoidance for ANKTIVA

MixedMedium impact
IBRX$9.38 −6.25%

ImmunityBio, Inc. (IBRX) announced that long-term Phase 2/3 trial results for its bladder cancer therapy ANKTIVA, administered alongside BCG, were published in the Journal of Urology. The study evaluated patients with BCG-unresponsive non-muscle invasive bladder cancer and reported an 84% cystectomy avoidance rate at three years, with complete responses lasting beyond 53 months. Severe Grade 3 treatment-related adverse events occurred in 4% of participants, while most side effects were mild. Shares of ImmunityBio fell 5.95% to $9.405 following the update.

The peer-reviewed publication provides extended clinical evidence supporting the durability and safety of ANKTIVA, which is already FDA-approved. Demonstrating multi-year bladder preservation with low rates of severe adverse events is key to driving clinical adoption and securing healthcare reimbursement. In addition, an FDA indication expansion in October 2026 to include papillary-only disease broadens the addressable market for the therapy.

Investors will monitor commercial sales growth and reimbursement traction to determine whether the published data and expanded indication lead to broader adoption. Key factors to watch going forward include real-world clinical outcomes, expanded insurance coverage, and potential head-to-head comparative effectiveness studies.

Key points

  • ImmunityBio published Phase 2/3 study results in the Journal of Urology showing an 84% cystectomy avoidance rate at three years for ANKTIVA plus BCG.
  • Complete responses in patients with BCG-unresponsive bladder cancer extended beyond 53 months, with Grade 3 adverse events in 4% of patients.
  • The FDA expanded ANKTIVA's indication in October 2026 to include papillary-only non-muscle invasive bladder cancer.
  • ImmunityBio shares fell 5.95% to $9.405 despite the positive long-term publication.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the key results from ImmunityBio's ANKTIVA study?

The Phase 2/3 trial showed an 84% cystectomy avoidance rate at three years and complete responses beyond 53 months in BCG-unresponsive bladder cancer, with Grade 3 adverse events in 4% of patients.

Has ANKTIVA received FDA approval?

Yes, ANKTIVA is FDA-approved, and the agency expanded its indication in October 2026 to include papillary-only non-muscle invasive bladder cancer.

How did ImmunityBio stock react to the trial publication?

ImmunityBio stock declined 5.95% to $9.405 following the release of the long-term clinical data.